Bridge Biotherapeutics Announces Public Recruitment for Shareholder-Nominated Outside Directors

Bridge Biotherapeutics logo (Photo by Bridge Biotherapeutics)

[Asia Economy Reporter Chunhee Lee] Innovative new drug research and development company Bridge Biotherapeutics announced on the 1st that it will hold its second shareholder-nominated outside director candidate recruitment this year, following the first in 2020.

Bridge Biotherapeutics established the 'shareholder-nominated outside director candidate recruitment system' in 2020, the year after entering the KOSDAQ market, as part of its management policy to establish governance.

This recruitment targets experts in the field of new drug research and development who have no disqualifications for appointment as outside directors. The process is conducted by receiving recommendations from shareholders who have held more than 246,379 shares, equivalent to at least 1% of the company's total issued shares, for more than six months as of November 30. Shareholders wishing to make recommendations can fill out the form attached to the announcement on the company’s website and submit it via the designated email. Applications will be accepted for two weeks from the 5th to the 18th. Outside director candidates collected through this shareholder nomination recruitment as well as those recommended by the existing board will undergo a series of evaluations to determine final appointments.

The newly appointed outside directors, who will be finalized through approval at the regular shareholders' meeting in March next year, will play a role in enhancing the efficiency of the company’s major research and development strategies and execution, based on expertise covering the entire cycle of innovative new drug research and development.

Meanwhile, Bridge Biotherapeutics continues to strive for the establishment of sound corporate governance through a board-centered major management decision-making system. The outside directors, composed of experts in key areas such as business development, corporate governance, and finance and accounting, convene the board of directors at least once a month on average to lead corporate decision-making. In addition, the company conducts investor-targeted corporate briefings and shareholder meetings to share mid- to long-term corporate strategies for growth as a global biotech, thereby enhancing market communication and trust.

This content was produced with the assistance of AI translation services.